Wnt/β-Catenin Signaling in Multiple Sclerosis: Navigating the Complex Path to Remyelination
Imagine waking up one day to find your body's own immune system attacking the vital insulation around your nerves, potentially leading to a lifetime of challenges like vision loss, weakness, or unsteady movements – that's the relentless battle faced by millions living with Multiple Sclerosis (MS). But here's where it gets intriguing: What if we could unlock a way to repair that damage and restore function? In this deep dive from Neuropathways, Kevin Chang, PharmD, unpacks the intricate world of remyelination in MS and explores the promising yet complicated role of Wnt/β-catenin signaling as a potential target for new therapies.
Multiple Sclerosis (MS) stands as a persistent inflammatory condition that damages the myelin sheath – the protective covering of nerves in the central nervous system (CNS). Globally, it impacts about 2.8 million individuals, often striking in early adulthood around age 32, and ranks among the top reasons for neurological disabilities in young people that aren't caused by trauma. Women bear a disproportionate burden, with roughly 63% of cases compared to 31% in men worldwide. Symptoms can vary widely, from the relapsing-remitting pattern where flare-ups alternate with recovery, to a steadily worsening progressive course. Patients might experience optic neuritis (inflammation of the optic nerve causing vision problems), sensory changes like numbness or tingling, muscle weakness, issues with balance and coordination (such as ataxia), bladder control troubles, or even problems with speech and swallowing due to cerebellar and brainstem involvement. While early stages are dominated by inflammation, long-term disability often ties more to the loss of nerve fibers (axons) and breakdowns in the body's repair processes rather than just how often relapses occur.
Currently, the go-to treatments are disease-modifying therapies (DMTs), which have revolutionized MS care by tackling immune system overactivity and brain inflammation. These medications work mainly by calming down the adaptive immune response, blocking white blood cells from entering the CNS, and cutting down on acute inflammatory harm. They've proven effective at reducing relapse rates and slowing disease progression. However, they fall short in directly fostering myelin repair or strengthening the blood-brain barrier (BBB) – the protective shield between the bloodstream and the brain. As a result, even with well-managed inflammation, many patients see their condition continue to deteriorate. This gap in treatment has sparked intense interest in remyelination as a strategy to combat the ongoing decline in MS.
Remyelination, the process of rebuilding the myelin sheath, relies on special cells called oligodendrocyte precursor cells (OPCs). These cells migrate to areas of demyelination (where myelin is stripped away) and transform into mature oligodendrocytes (OLs) that wrap nerves in new myelin. Successful remyelination speeds up nerve signal transmission, boosts recovery of function, and shields axons from further damage. Studies of MS brain tissue reveal that remyelination does happen, especially in fresh or active lesions, and patients with more robust remyelination tend to have milder disabilities. But in older, chronic lesions, OPCs linger without maturing, suggesting the problem isn't a lack of these cells but rather blocking signals in their surroundings that prevent differentiation. This points to a potential avenue: Targeting pathways that control OPC maturation could be a game-changer for promoting remyelination in MS.
Enter the Wnt/β-catenin pathway, a fundamental biological mechanism that's been around since early development and plays a key role in deciding cell fate, growth, and how cells specialize – particularly in the lineage of cells that make myelin. Researchers like Fancy and their team made a crucial discovery linking this pathway to remyelination. Using mouse models with toxin-induced demyelination, they spotted the transcription factor Tcf7l2 (also known as Tcf4) popping up in demyelinated areas during repair. In healthy adult brain tissue, Tcf4 is barely present, but it reappears in lesions as β-catenin signaling ramps up. When they artificially activated this genetically, differentiation slowed dramatically without affecting cell migration to the site – pinpointing differentiation as the main hurdle. Human MS samples mirrored this: Tcf7l2-positive cells appeared in active remyelinating lesions but vanished in chronic ones, directly tying Wnt activation to failed repair in real patients.
Building on this, later studies examined internal regulators of Wnt/β-catenin as drug targets, such as Axin2, a protein that helps break down β-catenin. Though Wnt signals boost Axin2 production, its levels are controlled by an enzyme called tankyrase through a process called PARsylation, which marks it for destruction. In failed remyelination, Axin2 RNA sticks around in stubborn OPCs, but tankyrase keeps its protein low, allowing Wnt signals to persist. Inhibiting tankyrase with drugs like XAV939 stabilizes Axin2, speeds up β-catenin breakdown, and enhances remyelination in normal mice – but not in mice lacking Axin2, proving the drug's specificity.
And this is the part most people miss: Wnt signaling's effects aren't one-size-fits-all; they depend on the cell type involved. Lengfeld and colleagues found that blocking it in endothelial cells (ECs) – which line blood vessels – actually made things worse in a mouse model of MS-like disease (experimental autoimmune encephalomyelitis or EAE). Using specially engineered mice where Wnt signaling could be turned off in ECs via doxycycline, they confirmed the shutdown by checking levels of Apcdd1, a gene that reflects Wnt activity. Compared to controls, these mice had more severe EAE symptoms (higher scores and mortality) because Wnt signaling in ECs helps maintain BBB integrity by reducing white blood cell entry, suppressing adhesion molecules, and limiting vesicle transport across the barrier. Removing this protection during EAE led to greater inflammation and poorer outcomes. This was echoed in research showing that teriflunomide, an MS drug, strengthens the BBB by boosting claudin-1 (a tight junction protein) through Wnt-2b activation.
But here's where it gets controversial: The external environment around lesions might also tweak Wnt's influence. Proteins called extracellular sulfatases (Sulf1 and Sulf2) are ramped up in MS lesions and hinder OPC function by amplifying Wnt and BMP (bone morphogenetic protein) signals, which block recruitment and maturation. Knocking out these sulfatases weakened those pathways, boosted OL numbers, and improved remyelination even with Wnt still active. Interestingly, pairing sulfatase inhibition with a Wnt blocker like XAV939 didn't add extra benefits, hinting that Wnt and BMP pathways funnel into the same downstream process. Could this mean sulfatases are a simpler target, sparing the need for Wnt manipulation?
Adding another twist, recent work has flipped the script on Tcf7l2, once seen as a pure roadblock to OL differentiation. Since it's common in repairing tissue but absent in inactive scars, it's a focal point for remyelination. Zhang and team used genetic experiments to show that Tcf7l2 actually aids differentiation by silencing BMP4, a myelination inhibitor. Deleting Tcf7l2 cranked up BMP4 signals, while overexpressing it dialed them down. And when they removed both Tcf7l2 and BMP4 together, myelin gene issues from Tcf7l2 loss alone were fixed. This reveals Tcf7l2 as a promoter of repair via BMP suppression, layering on more nuance for Wnt targeting. What are the implications for therapy? Is balancing these interactions the key, or does it introduce too many variables?
Pursuing fresh avenues like these to tackle MS's relentless progression is a bold, necessary move – but it's far from straightforward. The Wnt/β-catenin pathway holds exciting potential for remyelination therapies in MS, yet any interventions must be finely tuned, considering specific Wnt elements, which cells are affected, and how they intersect with other biological routes.
Figure 1: When Wnt signals are absent (Wnt-OFF), β-catenin in the cell's cytoplasm gets tagged for destruction by a complex including glycogen synthase kinase-3β (GSK3β), casein kinase 1 (CK1a), axis inhibition protein (AXIN), and adenomatous polyposis coli (APC). This leads to its breakdown via ubiquitination and the proteasome, silencing Wnt-related genes. In the active state (Wnt-ON), Wnt molecules latch onto Frizzled (Fz) receptors and co-receptors like LRP5/6, activating Dishevelled (Dsh). This dismantles the destruction complex, stabilizing β-catenin, which then moves to the nucleus to team up with TCF/LEF transcription factors and activate target genes.
REFERENCES
1. Atlas of MS 2020 - Epidemiology report. MS International Federation. Accessed December 8, 2025. https://www.msif.org/resource/atlas-of-ms-2020/
2. Lorenzut S, Negro ID, Pauletto G, et al. Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis. J Integr Neurosci. 2025;24(1):25081. doi:10.31083/JIN25081
3. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380-1390.e2. doi:10.1016/j.amjmed.2020.05.049
4. Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity–free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653-666. doi:10.1002/ana.25463
5. Cunniffe N, Coles A. Promoting remyelination in multiple sclerosis. J Neurol. 2021;268(1):30-44. doi:10.1007/s00415-019-09421-x
6. Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain J Neurol. 2010;133(10):2983-2998. doi:10.1093/brain/awq250
7. Fancy SPJ, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009;23(13):1571-1585. doi:10.1101/gad.1806309
8. Saraswat D, Shayya HJ, Polanco JJ, et al. Overcoming the inhibitory microenvironment surrounding oligodendrocyte progenitor cells following experimental demyelination. Nat Commun. 2021;12(1):1923. doi:10.1038/s41467-021-22263-4
9. Casaccia P. Anti-TANKyrase weapons promote myelination. Nat Neurosci. 2011;14(8):945-947. doi:10.1038/nn.2885
10. Lengfeld JE, Lutz SE, Smith JR, et al. Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis. Proc Natl Acad Sci U S A. 2017;114(7):E1168-E1177. doi:10.1073/pnas.1609905114
11. Zhao Y, Chen C, Xiao X, et al. Teriflunomide Promotes Blood–Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis. Mol Neurobiol. 2024;61(4):1936-1952. doi:10.1007/s12035-023-03655-7
12. Zhang S, Wang Y, Zhu X, et al. The Wnt Effector TCF7l2 Promotes Oligodendroglial Differentiation by Repressing Autocrine BMP4-Mediated Signaling. J Neurosci Off J Soc Neurosci. 2021;41(8):1650-1664. doi:10.1523/JNEUROSCI.2386-20.2021
13. Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3. doi:10.1038/s41392-021-00762-6
Newsletter
Stay ahead in the world of neurology – sign up for NeurologyLive to get expert chats, fresh research findings, and updates on cutting-edge treatments.
What are your thoughts on diving into Wnt/β-catenin for MS treatments? Do you see it as a promising leap forward, or does the complexity make you cautious? Share your opinions in the comments – is there a controversial angle here we've missed, like potential side effects on other body systems? Let's discuss!
